Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CODEXIS, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 2.470 USD | +4.66% | +21.67% | -47.00% | |
| Nov. 08 | North American Morning Briefing : Stock Futures -2- | DJ |
| Nov. 07 | Benchmark Downgrades Codexis to Hold From Buy | MT |
Financials (USD)
| Sales 2023 * | 60.56 M | Sales 2024 * | 57.65 M | Capitalization | 172 M |
|---|---|---|---|---|---|
| Net income 2023 * | -80.00 M | Net income 2024 * | -46.00 M | EV / Sales 2023 * | 2,85x |
| Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 2,99x |
| P/E ratio 2023 * | -2,10x | P/E ratio 2024 * | -3,75x | Employees | 248 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 97.32% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +4.66% | ||
| 1 week | +21.67% | ||
| Current month | +4.66% | ||
| 1 month | +37.22% | ||
| 3 months | +37.22% | ||
| 6 months | -6.08% | ||
| Current year | -47.00% |
1 week
1.97
2.55
1 month
1.512.55
Current year
1.456.98
1 year
1.456.98
3 years
1.4542.01
5 years
1.4542.01
10 years
1.2442.01
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Dilly
CEO | Chief Executive Officer | 63 | 2020 |
Sriram Ryali
DFI | Director of Finance/CFO | 42 | Jan. 22 |
| Compliance Officer | 52 | Oct. 31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Smith
BRD | Director/Board Member | 63 | 2016 |
Rahul Singhvi
BRD | Director/Board Member | 58 | 2022 |
Stephen Dilly
CEO | Chief Executive Officer | 63 | 2020 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.09% | 0 M€ | 0.00% | - | |
| 0.81% | 69 M€ | -16.48% | ||
| 0.79% | 55 M€ | -11.84% | - | |
| 0.55% | 2 M€ | +13.47% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-01 | 2.470 | +4.66% | 777,681 |
| 23-11-30 | 2.360 | -2.88% | 564,024 |
| 23-11-29 | 2.430 | +7.05% | 827,996 |
| 23-11-28 | 2.270 | +5.09% | 662,510 |
| 23-11-27 | 2.160 | +6.40% | 681,100 |
Delayed Quote Nasdaq, December 01, 2023 at 04:00 pm EST
More quotes
Codexis, Inc. is an enzyme engineering company. The Company is engaged in discovering, developing and selling enzymes and other proteins. The Company commercializes its CodeEvolver enzyme engineering technology platform and products in the manufacture of small molecule pharmaceuticals. It operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Performance Enzymes segment consists primarily of two focus areas: biocatalysts for the sustainable manufacturing of pharmaceuticals, and enzymes for life science applications, including genomic sequencing and nucleic acid synthesis. The Novel Biotherapeutics segment offers product candidates include enzymes that are orally administered for function in the gastrointestinal tract (GI), such as its partnered product candidates CDX-7108 for the treatment of exocrine pancreatic insufficiency and CDX-6114 for the treatment of phenylketonuria, which are both in Phase I clinical trials.
Calendar
2023-12-08
- Investor Meeting - Key Opinion Leader
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.470USD
Average target price
5.833USD
Spread / Average Target
+136.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -47.00% | 172 M $ | |
| +65.53% | 40 132 M $ | |
| +5.87% | 39 586 M $ | |
| -55.56% | 30 438 M $ | |
| -26.11% | 28 571 M $ | |
| +38.66% | 22 175 M $ | |
| -27.87% | 21 511 M $ | |
| +1.62% | 17 412 M $ | |
| -13.43% | 11 313 M $ | |
| -7.44% | 10 346 M $ |
